Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Novacyt ( (FR:ALNOV) ) has shared an announcement.
Novacyt S.A. has announced that it has received IVDR accreditation for its Yourgene® QST*R Base assay, a Class C in vitro medical device designed for rapid diagnosis of common autosomal and sex chromosome aneuploidies during pregnancy. This accreditation demonstrates the company’s capability to meet stringent EU regulatory requirements and reinforces the high quality and accuracy of its reproductive health tests, enhancing its market position in molecular diagnostics.
More about Novacyt
Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on genomic medicine. The company develops, manufactures, and commercializes molecular assays and instrumentation for human health, animal health, and environmental sectors. Novacyt is headquartered in Le Vésinet, France, with offices in the UK, Singapore, the US, and Canada, and has a commercial presence in over 65 countries. It is listed on the London Stock Exchange’s AIM market and on the Paris Stock Exchange Euronext Growth.
YTD Price Performance: -2.10%
Average Trading Volume: 282
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $43.87M
For a thorough assessment of ALNOV stock, go to TipRanks’ Stock Analysis page.
